Navigation Links
Epitomics, Inc. and University of California, Davis, Complete Star Program for High-Throughput Measurement of Antibody-Antigen Interactions
Date:12/21/2011

BURLINGAME, Calif., Dec. 21, 2011 /PRNewswire/ -- Epitomics, Inc., a California based biotech company, announced today that they have successfully completed a Star Program in collaboration with the University of California, Davis, which has resulted in the application of a new, advanced antibody assay technique, a label-free optical microarray detection platform, for high-throughput measurements of antibody-antigen interactions. Over the course of the project, more than 100 rabbit monoclonal antibodies (RabMAbs) raised against clinical cancer biomarkers were analyzed and determined to possess affinities ranging from 10-9 to 10-13 M, with an average of 10-10 M. The affinity values measured using this label-free optical microarray detection process were found to be consistent with those measured using the established BIAcore technology, based on a random sampling of the RabMAb population.

"I am very excited about our new technology which can provide consistent results compared to the established BIAcore technology but in a high throughput manner.  I am also impressed with high affinities of RabMAbs," said Dr. Xiangdong Zhu, a Professor in Physics at the University of California, Davis, who was the inventor of the label-free optical microarray detection technology used in the program.

"It is widely accepted that rabbits produce higher affinity antibodies than mice, but this had not previously been demonstrated with a large population of monoclonal antibodies. With the availability of this novel technology, we were able to demonstrate that RabMAbs have consistently high affinities through the measurement of a large collection of RabMAbs," said Dr. Guo-Liang Yu, CEO, Epitomics, Inc.

About Epitomics
Epitomics, Inc., an emerging biotechnology company, is dedicated to developing breakthrough monoclonal antibody technology for research and diagnostic applications. The company utilizes a unique and proprietary RabMAb® (Rabbit Monoclonal Antibody) technology which produces antibodies with superior binding affinity, specificity and bioactivity both in vitro and in vivo. Epitomics, Inc. is headquartered in Burlingame, California, and operates wholly owned subsidiaries in Hong Kong and Hangzhou, the People's Republic of China.  For more information about Epitomics, please visit www.epitomics.com.


'/>"/>
SOURCE Epitomics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Epitomics, Inc. Receives Notice of Allowance from the United States Patent and Trademark Office for a Novel Method for Identifying Differentially Expressed Proteins
2. Epitomics, Inc. Announces Worldwide Availability of LRRK2 Antibodies Developed in Partnership With The Michael J. Fox Foundation
3. HistoRx Licenses Melanoma Assay from Yale University
4. Causes of Gulf War Illness are complex and vary by deployment area -- Baylor University study
5. BioRestorative Therapies Signs Material Manufacturing Agreement With University of Utah
6. Arizona State University engineers aim to improve performance of technology in extreme environments
7. Bright Light into the Ear Canal Treats Seasonal Depression Effectively in Two Clinical Trials Presented by Valkee and University of Oulu
8. IDEXX Laboratories Acquires the RADIL Reference Laboratory from the University of Missouri
9. University of Toronto engineers solve energy puzzle
10. The Medical University of Vienna and Vienna General Hospital Perform the First two Commercial Implants Worldwide of Sequana Medicals ALFApump® System
11. University of Toronto researchers create worlds most efficient flexible OLED on plastic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... (PRWEB) , ... October 10, 2017 , ... ... innovation and business process optimization firm for the life sciences and healthcare industries, ... conference in San Francisco. , The presentation, “Automating GxP Validation for Agile ...
(Date:10/9/2017)... SAN DIEGO , Oct. 9, 2017 /PRNewswire/ ... a biological mechanism by which its ProCell stem ... of critical limb ischemia.  The Company, demonstrated that ... the amount of limbs saved as compared to ... of the molecule HGF resulted in reduction of ...
(Date:10/9/2017)... (PRWEB) , ... October 09, 2017 , ... At its ... Dr. Christopher Stubbs, a professor in Harvard University’s Departments of Physics and Astronomy, has ... was a member of the winning team for the 2015 Breakthrough Prize in Fundamental ...
(Date:10/9/2017)... ... October 09, 2017 , ... ... journal, Epilepsia, Brain Sentinel’s SPEAC® System which uses the surface electromyography (sEMG) ... tonic-clonic seizures (GTCS) using surface electromyography (sEMG). The prospective multicenter phase III ...
Breaking Biology Technology:
(Date:5/23/2017)... robotic gym for the rehabilitation and functional motor sense evaluation of lower ... . The first 30 robots will be available from June in ... The technology was developed and patented at the IIT laboratories and has ... to a 10 million euro investment from entrepreneur Sergio Dompè. ... ...
(Date:4/24/2017)... Janice Kephart , former 9/11 ... Partners, LLP (IdSP) , today issues the following ... March 6, 2017 Executive Order: Protecting the ... be instilled with greater confidence, enabling the reactivation ... applications are suspended by until at least July ...
(Date:4/13/2017)... , April 13, 2017 UBM,s Advanced Design ... will feature emerging and evolving technology through its ... Summits will run alongside the expo portion of the ... panels and demonstrations focused on trending topics within 3D ... design and manufacturing event will take place June 13-15, 2017 ...
Breaking Biology News(10 mins):